We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Yourgene Health Plc | LSE:YGEN | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.515 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
17/3/2023 08:03 | Some good news at last! About 6 years too late. At least one more to go hopefully! | birdie12 | |
14/3/2023 14:49 | Just mainly small pi trades bar one sizeable one. People are fed up with the radio silence. Needs some good news pdq. | birdie12 | |
14/3/2023 14:35 | Looks like it’s gonna go through the placing price at this rate. And I don’t think that’s a tree shake. | major courtenay | |
13/3/2023 14:26 | basically a 6.6M euro framework contract . | birdie12 | |
13/3/2023 14:21 | Oh! I thought it had translated. Is there not a translation button? Top right hand corner for translations. | birdie12 | |
13/3/2023 14:12 | My French isn’t up to par. Care to elaborate birdie? | major courtenay | |
13/3/2023 13:50 | LOL! agreed. There should be plenty of news coming along. This is interesting too... | birdie12 | |
13/3/2023 12:53 | You could well be right birdie. Time will tell, but I did do a modest top up earlier. When you can buy well under the mid and so close to the placing price, it seems rude not to. | major courtenay | |
13/3/2023 12:47 | Why would they shuffle off now at this price? They will expect to multi bag, same as me. Just fed up short term pi with another rainbow to chase. | birdie12 | |
13/3/2023 11:26 | Buying under the mid price. Wouldn’t be surprised if the price comes down. I wonder if some of the placees are shuffling off. Unless anyone has any alternative thoughts? | major courtenay | |
13/3/2023 07:43 | Looks like management were on the case anyway. Still a relief though. | birdie12 | |
12/3/2023 22:37 | TW having his say,,anyone subscribed? | birdie12 | |
12/3/2023 21:39 | ADVFN Advised through help thread that fundamental data wrong. Not nearly as tasty a nibble now - | pugugly | |
12/3/2023 21:03 | PUG, they are wrong! Nearer £10M | birdie12 | |
12/3/2023 21:00 | The only debt is what is owed to SVB, and the IP is worth millions. | birdie12 | |
12/3/2023 20:58 | birdie12. I was going by the figure from the Advfn quote and the financials. | pugugly | |
12/3/2023 20:53 | PUG, you on the wrong BB? Mcap £2.3M er don't think so! | birdie12 | |
12/3/2023 20:51 | not much point calling in the loans early as they can't pay it because they have no cash to pay it remember! | birdie12 | |
12/3/2023 20:47 | Deleted as figures and value taken from Advfn fundamentals are WRONG!! See correction post 3169 below | pugugly | |
12/3/2023 20:43 | how do you know they haven't drawn down the lot? | birdie12 | |
12/3/2023 20:31 | an offer has already been made for SVB UK. A consortium led by the Bank of London. | birdie12 | |
12/3/2023 19:47 | pug - I think the only insuperable problem would be if svb wanted to call in the loans to maintain its own balance sheet. I think we really just have to wait and see what the Chancellor proposes as a help scheme. | supernumerary | |
12/3/2023 19:39 | YGEN and SVP@yourgene owe,rather than have trapped deposits.However, if they need the outstanding 0.9M then they'll need supportAt the beginning of 2022, AIM-quoted diagnostics firm Yourgene Healthcare entered into a three-year, £5m loan facility with Silicon Valley Bank. There was £4.1m drawn down by September 2022 when net debt was £1.7m.A placing and retail offer raised £6.8m at 0.3p a share, after expenses. This was required for working capital and product development. That should provide the required cash for the business until at least the third quarter of 2023. Singer forecasts net debt of £2.2m by the end of March 2024. The Taiwan subsidiary is being sold, and a strategic investor is being sought. | pharmaboy3 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions